Literature DB >> 318684

Hereditary deficiency of the third component of complement in a child with fever, skin rash, and arthralgias: response to transfusion of whole blood.

S G Osofsky, B H Thompson, T F Lint, H Gewurz.   

Abstract

A previously well 34-month-old male presenting with fever, skin rash, and arthralgias was found to lack C3 by immunochemical (undetectable) and hemolytic (1% normal) assays. No infectious agent could be demonstrated. Protein levels of Clq. C4, C5, properdin, and C3b-INA and hemolytic activities of complement components C1 to C9 except C3 were normal or elevated; total hemolytic complement activity was 13% of normal and was reconstituted by purified C3. Properdin factor B was 702 (normal 175 to 275) mug/ml, and was not cleaver upon addition of zymosan or cobra venom factor. The serum had normal immune adherence activity, but was deficient in ability to opsonize Candida albicans for uptake and Escherichia coli for killing by neurophils, generate neutrophil chemotactic factors and inhibit the growth of E. coli; these activities were restored by purified C3. A transfusion of 320 ml 1-hour-old normal whole blood on the fifty-second day resulted in transitory elevation of the C3 level to 25 mg/dl with a fall-off (approximately 2 1/2% per hour) to undetectable levels by 69 hours; it was followed by disappearance of the skin rash and arthralgias and return to normal of the previously elevated temperature and CRP levels. C3 levels in family members (seven of 24 half-normal), lack of anti-C3 activity, normal C3b-INA levels and a normal rate of catabolism of transfused C3 indicated that the deficiency was inherited with autosomal codominance and involved decreased synthesis of C3. Thus, this child is a unique individual with inherited C3 deficiency presenting with absence of repeated infections, whose symptoms of fever, skin rash, and arthralgia were abated by whole blood transfusion.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 318684     DOI: 10.1016/s0022-3476(77)80626-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

1.  Homozygous hereditary C3 deficiency due to a premature stop codon.

Authors:  Edimara Da Silva Reis; Gisele Vanessa Baracho; Adriana Sousa Lima; Chuck S Farah; Lourdes Isaac
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

Review 2.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

3.  Combined homozygous factor H and heterozygous C2 deficiency in an Italian family.

Authors:  M Brai; G Misiano; S Maringhini; I Cutaja; G Hauptmann
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

4.  Complement in cystic fibrosis.

Authors:  M Götz; G Lubec
Journal:  Eur J Pediatr       Date:  1978-01-17       Impact factor: 3.183

Review 5.  Lupus diseases associated with hereditary and acquired deficiencies of complement.

Authors:  V Agnello
Journal:  Springer Semin Immunopathol       Date:  1986

Review 6.  Inherited deficiencies of complement proteins in man.

Authors:  C A Alper; F S Rosen
Journal:  Springer Semin Immunopathol       Date:  1984

Review 7.  The complement system: its importance in the host response to viral infection.

Authors:  R L Hirsch
Journal:  Microbiol Rev       Date:  1982-03

8.  Molecular basis of hereditary C3 deficiency.

Authors:  M Botto; K Y Fong; A K So; A Rudge; M J Walport
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

9.  Homozygous hereditary C3 deficiency due to a partial gene deletion.

Authors:  M Botto; K Y Fong; A K So; R Barlow; R Routier; B J Morley; M J Walport
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

10.  Biosynthesis of the third component of complement (C3) in vitro by monocytes from both normal and homozygous C3-deficient humans.

Authors:  L P Einstein; P J Hansen; M Ballow; A E Davis; J S Davis; C A Alper; F S Rosen; H R Colten
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.